NewsBenzingaBeam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT Benzinga 2026.10.13 11:14 (GMT+0) Open on Benzinga Other news U.S. Diplomat In Riyadh, Microsoft Arabia President Ayman Al-Ghamdi Discussion Expansion Of U.S.-Saudi Partnership In Super Intelligence, Cloud Computing Wells Fargo Maintains Overweight on Matador Resources, Lowers Price Target to $76 UnitedHealth Analysts Slash Their Forecasts Following Q3 Results Wells Fargo Maintains Equal-Weight on Magnolia Oil & Gas, Lowers Price Target to $30 Google DeepMind’s Demis Hassabis Calls AI Hacking Incidents ‘Early Warning Shots,’ Warns of More Major Threats Ahead Without Stronger Safeguards Wells Fargo Maintains Overweight on Chord Energy, Lowers Price Target to $174
U.S. Diplomat In Riyadh, Microsoft Arabia President Ayman Al-Ghamdi Discussion Expansion Of U.S.-Saudi Partnership In Super Intelligence, Cloud Computing
Google DeepMind’s Demis Hassabis Calls AI Hacking Incidents ‘Early Warning Shots,’ Warns of More Major Threats Ahead Without Stronger Safeguards
